Friday 05 August 2022

California-based biopharmaceutical company Gilead Sciences, Inc. (NASDAQ: GILD) and MiroBio, has agreed to acquire UK-based clinical-stage biotechnology company MiroBio for approximately USD 405m in cash, the company said.

Under the terms of the agreement, Gilead will acquire all of the outstanding share capital of MiroBio.

The acquisition will provide Gilead with MiroBio's proprietary discovery platform and its entire portfolio of immune inhibitory receptor agonists.

Cowen is acting as financial advisor to Gilead. Centerview Partners is acting as financial advisor to MiroBio.

Davis Polk and Wardwell LLP, Mayer Brown LLP, and Mishcon de Reya LLP are serving as legal counsel to Gilead, and Goodwin Procter LLP and Wilson Sonsini Goodrich and Rosati are serving as legal counsel to MiroBio.

MiroBio is a private biotechnology company whose mission is to develop a new class of therapeutic agents, checkpoint agonist antibodies, to restore immune balance in autoimmune patients.

MiroBio is backed by international investors including Oxford Science Enterprises, Samsara BioCapital, SR One, Medicxi, Advent Life Sciences, OrbiMed and Monograph.